Related Experiment Video
Updated: May 30, 2026
08:46
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Prasugrel resistance: fact or fiction
1Department of Cardiology, Patras University Hospital, Rio, Patras, Greece. dalex@med.upatras.gr
Platelets
|July 27, 2011
Summary
Prasugrel effectively inhibits platelet aggregation by blocking the P2Y12 receptor. However, this review examines the prevalence, mechanisms, and clinical impact of occasional prasugrel resistance, where platelet inhibition is inadequate.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Thrombosis Research
Background:
- Prasugrel is a potent P2Y12 receptor antagonist.
- It offers superior platelet inhibition compared to clopidogrel in patients.
- Occasional cases of prasugrel resistance have been reported.
Purpose of the Study:
- To review the prevalence of prasugrel resistance.
- To elucidate the underlying mechanisms of prasugrel resistance.
- To discuss the potential clinical implications of prasugrel resistance.
Main Methods:
- Literature review of studies on prasugrel and platelet aggregation.
- Analysis of reported cases of prasugrel resistance.
- Examination of pharmacological data on P2Y12 receptor antagonism.
Main Results:
- Prasugrel demonstrates rapid and consistent platelet inhibition.
- A subset of patients exhibits inadequate platelet response to prasugrel.
- Mechanisms of resistance may involve drug metabolism, receptor expression, or patient-specific factors.
Conclusions:
- While prasugrel is highly effective, resistance is a recognized phenomenon.
- Understanding resistance mechanisms is crucial for optimizing antiplatelet therapy.
- Further research is needed to manage patients with prasugrel resistance.
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...